Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Save, Nehali
- Tamsulosin for the Treatment of Voiding Dysfunction in Women – A Review
Abstract Views :227 |
PDF Views:0
Authors
Affiliations
1 Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, IN
1 Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, IN
Source
The Indian Practitioner, Vol 71, No 10 (2018), Pagination: 34-38Abstract
Lower urinary tract symptoms (LUTS) have high prevalence worldwide in the aging population including both, men and women and with the advancing age, the incidence of LUTS continues to increase. Interference of the symptoms with the daily activities has a negative impact on the quality of life of many individuals. Apart from watchful waiting and surgery, medical therapies have shown to provide significant control of LUTS. α1- adrenergic receptor blockers are used as first-line therapy for men to alleviate Benign Prostatic Hyperplasia (BPH) induced urinary symptoms. Similar underlying etiology of LUTS in men and women proposes the utility of α1-adrenergic receptor blockers for female lower urinary tract symptoms (FLUTS). Tamsulosin, the highly uroselective α1-adrenergic receptor blocker, has steadily borne positive results in symptomatic management of FLUTS. Improvement in quality of life has been a vital criteria in the assessment of the efficacy of Tamsulosin. All the reviewed studies substantiate the safety and tolerability of Tamsulosin. Numerous clinical trials of Tamsulosin in women suggest the suitability of Tamsulosin as an appropriate therapeutic option for management of female LUTS.Keywords
Tamsulosin, Luts/ Fluts, α1-adrenergic Receptors, Bladder, Urethra.
References
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P.
- Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 2006; 50(6):1306-15
- Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. International urology and nephrology 2012;44(6):1649-56.
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.
- Goodwin J.(2012) Incontinence Affects Young Childless Women, Too. HealthDay®https://consumer.healthday.com/senior-citizen-information-31/age-health-news-7/incontinenceaffects-young-childless-women-too-666623.html Accessed 25 August 2016.
- Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU international. 2009;104(3):352-60.
- Booth AM. Physiology of the urinary bladder and urethra. Annals of internal medicine.1980. 92(2_Part_2):312-5.
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.
- Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, WeinAJ.How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international.2001;87(9):760-6.
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50(6):1306-15.
- Wagg AS, Cardozo L, Chapple C, De Ridder D, Kelleher C, Kirby M, Milsom I, Vierhout M. Overactive bladder syndrome in older people. BJU international .2007;99(3):502-9.
- Patel R, Nitti VW.Bladder outlet obstruction in women: prevalence, recognition, and management. Current urology reports.2001;2(5):379-87.
- Andersson, K. E., &Gratzke, C. Pharmacology of the lower urinary tract. Textbook of the neurogenic bladder 2008; 2:81-100.
- Schwinn DA. Novel role for α1‐adrenergic receptor subtypes in lower urinary tract symptoms. BJU international.2000; 86(s2):11-22.
- Price D. Potential mechanisms of action of superselective α1adrenoceptor antagonists.European urology .2001;40(Suppl. 4):5-11.
- Urinary incontinence: The management of urinary incontinence in women; NICE Clinical Guideline (2013), Royal College of Obstetricians and Gynecologists. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/themanagementof-urinary-incontinence-in-women-nice-clinicalguideline-171/ Accessed 6 May 2016
- Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults.Cochrane Database of Systematic Reviews.2012;Issue 12. Art. No.: CD003193.
- Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events; Drug Safety Update, Medicines and Healthcare products Regulatory Agency (MHRA). (2015). https://www.gov.uk/drug-safetyupdate/mirabegron-betmiga-risk-of-severe-hypertensionand-associated-cerebrovascular-and-cardiac-events Accessed 31 May 2016
- Boyd K, Hilas O. α-Adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Annals of Pharmacotherapy.2014;48(6):711-22.
- Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostate. Journal of autonomic pharmacology. 1996;16(1):21-8.
- Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. European Journal of Pharmacology: Molecular Pharmacology.1995;288(2):201-7.
- Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British journal of clinical pharmacology.1998;45(1):49-55.
- Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia.Reviews in urology. 2007;9(4):181.
- Reitz A, Haferkamp A, Kyburz T, Knapp PA, Wefer B, Schurch B. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. European urology. 2004;46(2):235-40.
- Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian Journal of Surgery .2007;30(2):131-7.
- Lee KS, Han DH, Lee YS, Choo MS, Yoo TK, Park HJ, Yoon H, Jeong H, Lee SJ, Kim H, Park WH. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. Journal of Korean medical science .2010; 25(1):117-22.
- Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of α1‐blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. International journal of urology. 2003;10(11):576-81.
- Lee S, Lee W, Lee S, Kim H, Park C. The effect oftamsulosin in female patients with lower urinary tractsymptoms and predictive factors for therapeutic outcome:multicenter, prospective study. IntUrogynecol J.2011;22(suppl 3):S1781.
- Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, MorgiaG.Use of α1-blockers in female functional bladder neck obstruction. Urologia internationalis.2005;74(3):256-61.
- Ryu S, Kim S, Hwang E, Im C, Oh K, Jung S et al.The role of alpha 1(A) adrenoreceptor antagonist tamsulosinfor the treatment of patients with lower urinary tractsymptoms in women: the effect of nocturia and sleep quality. Urology.2010; 76(suppl 3A):S61.
- Hajebrahimi S, Asrbadr YA, Azaripour A, Sadeghi-Bazargani H. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial. International journal of general medicine. 2011;4:35.
- Costantini E, Lazzeri M, Bini V, Zucchi A, Fioretti F, Frumenzio E, Porena M. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urologia internationalis.2009;83(3):311-5.
- Kim SO, Hwang EC, Oh KJ, Kwon D, Park K, Ryu SB. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. International urogynecology journal.2011;22(10):1287-91.
- Neĭmark, AI, Razdorskaia, MV, Kondrat’eva, I., &Muzalevskaia, NI . [Correction of urodynamic disorders in women with obstructive urination]. Urologiia (Moscow, Russia: 1999), 2012;(5), 34-37.
- Essential Immunonutrients in COVID-19: An Evidence-Based Review
Abstract Views :217 |
PDF Views:0
Authors
Affiliations
1 President- Medical & Regulatory Affairs Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Assistant General Manager- Medical, Scientific Department, Aristo Pharmaceuticals Private Limited, IN
3 Sr. Scientific Executive- Scientific Department, Aristo Pharmaceuticals Private Limited, IN
1 President- Medical & Regulatory Affairs Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Assistant General Manager- Medical, Scientific Department, Aristo Pharmaceuticals Private Limited, IN
3 Sr. Scientific Executive- Scientific Department, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 74, No 6 (2021), Pagination: 20-26Abstract
A ‘well-fed’ immune system is extremely important to ensure it performs the function of protecting against the viral offense. Various nutrients and minerals play a vital role in maintaining the integrity and function of the immune system. Among the various nutrients and minerals, vitamin C, vitamin D, and zinc stand out for having immune-modulatory functions which are demonstrated in a substantial body of evidence. In the ongoing pandemic of COVID-19, nutrients that can optimize the immune system to prevent or lower the risk of severe disease progression are very essential. Medical literature shows that deficiency of one or more of these nutrients may affect the immunity status of an individual and may predispose a person to an adverse prognosis of COVID-19. Therefore, adequate intake of vitamin C, D, and zinc may present as a promising tool in prehabilitation with immunonutrition for COVID-19 prevention and management. This review provides a comprehensive overview of the role of vitamin C, D, and zinc as an immunomodulatory agent in COVID-19 management.Keywords
Vitamin C, vitamin D, zinc, immunity, immunonutrition, COVID-19References
- Mahalmani VM, Mahendru D, Semwal A, Kaur S, Kaur H,
- Sarma P, et al. COVID-19 pandemic: A review based on current evidence. Indian J Pharmacol. 2020 Mar-Apr;52(2):117-129.
- Lai CC, Shih TP, Ko WC, Tang HJ and Hsueh PR. Severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial
- agents. 2020;55(3), p.105924.
- Chowdhury MA, Hossain N, Kashem MA, Shahid MA,
- Alam A. Immune response in COVID-19: A review. J Infect
- Public Health. 2020;13(11):1619-1629.
- Maladkar M, Tekchandani MC, Karchodi MA. COVID-19
- Treatment: Current and Emerging Options. The Indian
- Practitioner. 2020;73(6):37-41.
- Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020;256:117900.
- Zhong J, Tang J, Ye C, Dong L. The immunology of
- COVID-19: is immune modulation an option for treatment?
- The Lancet Rheumatology. 2020;2(7):e428-e436.
- Calder PC. Nutrition, immunity and COVID-19. BMJ
- Nutrition, Prevention & Health. 2020; 3(1), p.74.
- Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? BMJ Nutrition,
- Prevention & Health. 2020;3(1):100.
- Burns JJ,. Missing step in man, monkey and guinea pig
- required for the biosynthesis of L-ascorbic acid. Nature.
- ;180(4585):pp.553-553.
- Schleicher RL, Carroll MD, Ford ES, and Lacher DA.. Serum
- vitamin C and the prevalence of vitamin C deficiency in the
- United States: 2003–2004 National Health and Nutrition
- Examination Survey (NHANES). The American journal of clinical nutrition. 2009;90(5): pp.1252-1263.
- Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in
- humans. Am J Clin Nutr. 1999; 69(6):1086-107.
- Maxfield L, Crane JS. Vitamin C Deficiency. [Updated 2020
- Jul 2]. In: StatPearls [Internet]. [cited 2021 Jun 09] Available
- from: https://www.ncbi.nlm.nih.gov/books/NBK493187/
- Carr AC and Maggini S. Vitamin C and immune function.
- Nutrients.2017; 9(11), p.1211.
- Carr AC, Rowe S. The Emerging Role of Vitamin C in the
- Prevention and Treatment of COVID-19. Nutrients. 2020;
- (11):3286.
- Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE,
- et al. Vitamin C—An Adjunctive Therapy for Respiratory
- Infection, Sepsis and COVID-19. Nutrients. 2020;12(12):3760.
- Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C,
- Farthing CA, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. Journal of translational
- medicine. 2014; 12(1), pp.1-10.
- Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K,
- Ruzinski JT, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients.
- Annals of surgery. 2002;236(6):814.
- Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J.
- Hydrocortisone, vitamin C, and thiamine for the treatment
- of severe sepsis and septic shock: a retrospective before-after
- study. Chest. 2017;151(6):1229-38.
- Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M,
- Bontempo P, et al. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a
- prospective, randomized, double-blind, placebo-controlled
- trial. Anesthesia & Analgesia. 2004;99(3):857-63.
- Feyaerts AF and Luyten W. Vitamin C as prophylaxis and
- adjunctive medical treatment for COVID-19? Nutrition. 2020;
- , p.110948.
- Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treat-ment and prevention. Rev Endocrine
- Metab Disord. 2017;18:153–65
- Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of infection and public
- health. 2020;13(10): 1373-1380
- Grant WB, Al Anouti F, Moukayed M. Targeted 25- hydroxyvitamin D concentration measurements and vitamin
- D3 supplementation can have important patient and public
- health benefits. Eur J Clin Nutr. 2020;74:366–76.
- Sassi F, Tamone C and D’Amelio P. Vitamin D: nutrient,
- hormone, and immunomodulator. Nutrients. 2018;10(11),
- p.1656.
- Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP.
- Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142-53.
- Li YC. Vitamin D regulation of the renin–angiotensin system. Journal of cellular biochemistry. 2003;88(2):327-31.
- Zittermann A, Gummert JF. Nonclassical vitamin D actions. Nutrients. 2010;2(4):408-25.
- Lai YH, Fang TC. The pleiotropic effect of vitamin D. ISRN nephrology. 2013; Article ID 898125
- Kalia V, Studzinski GP, Sarkar S. Role of vitamin D in regulating COVID-19 severity—An immunological perspective. Journal of Leukocyte Biology. J Leukoc Biol. 2021;1–11
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
- Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: A randomized place bo-controlled trial. APMIS. 2019; 127:681–687.
- Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.
- Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PloS one. 2013;8(6):e65835.
- Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. Journal of pharmacology & pharmacotherapeutics. 2012;3(4):300.
- Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356.
- Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebocontrolled, study (SHADE study). Postgraduate medical journal. Postgrad Med J 2020;0:1–4.
- Saper RB, Rash R. Zinc: an essential micronutrient. American family physician. 2009;79(9):768.
- Zinc Deficiency in Humans affecting Immune System [Internet]. [cited 2021 Jun 06]. Available from: https://indiacsr.in/zinc-deficiency-humans-affecting-immune-system/
- Yanagisawa H. Zinc deficiency and clinical practice. Japan Medical Association Journal. 2004;47(8):359-64.
- Chasapis CT, Ntoupa PS, Spiliopoulou CA, Stefanidou ME. Recent aspects of the effects of zinc on human health. Archives of toxicology. 2020;94:1443-60.
- Prasad AS. Zinc in human health: effect of zinc on immune cells. Molecular medicine. 2008;14(5):353-7.
- Berger A. What does zinc do? BMJ. 2002;325(7372):1062.
- Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. Zinc and respiratory tract infections: Perspectives for COVID-19. International journal of molecular medicine. 2020;46(1):17-26.
- Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. The American journal of clinical nutrition. 2007;85(3):837-44.
- Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. Cmaj. 2012;184(10):E551-61.
- Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv. 2020.
- Frontera JA, Rahimian JO, Yaghi S, Liu M, Lewis A, de Havenon A, et al. Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. Res Sq [Preprint]. 2020;rs.3.rs-94509.
- COVID-19 Treatment Guidelines [Internet]. [cited 2021 Jun 06]. Available from: https://www.covid19treatmentguidelines.nih.gov/supplements/zinc/